Locations
 
WEBSITES
  • United States (English)
  • International (English)
  • Chinese (中文)
  • French (Français)
  • German (Deutsch)
  • Italian (Italiano)
  • Japanese (日本語)
  • Russian (Русский)
  • Whole Blood Technologies
 

Leaving U.S. website

You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

YesNo
  • Investor Relations
  • PORTALS
    • IMPACT Online
    • HaemoLink™
  • LOGIN
    • Haemonetics
    • HSS Client Login
    • IMPACT Online
    • Software Download Center
  • REGISTER
  • Home
  • Products
     
    U.S. ProductsView International Products View U.S. Whole Blood Technologies
    Devices
    Surgical and Diagnostic Devices
    • Cell Saver Elite+
    • Cell Saver 5+
    • OrthoPAT
    • SmartSuction Harmony
    • TEG 5000
    Blood and Plasma Center Devices
    • ACP 215
    • MCS+ 8150
    • MCS+ 9000
    • NexSys PCS
    • PCS 2
    Software
    Blood Center Software
    • Donor Doc
    • Donor Doc Phlebotomy
    • eDonor
    • ElDorado Donor
    • Hemasphere
    • Surround
    Hospital Software
    • BloodTrack
    • SafeTrace Tx
    Plasma Center Software
    • Cash Card
    • DMS
    • eQue
    • Logic
    • NextGen
    Services
    Consulting Services
    • Education and Change Management
    • IMPACT Online
    • Process Improvement
    Software Services
    • Software Services Overview
    • Client Support
    • Education Services
    • Implementation Services
    • Technical Services
    • Validation Services
    • Software Solutions Partners
     
  • Solutions
     
    Blood Management Solutions
    • Solutions for Blood Centers
    • Solutions for Hospitals
    • Solutions for Plasma Centers
    • Software Solutions
    • Donor Process Automation
     
  • Learning Center
     
    Product Training
    • All Products
    • Blood Centers
    • Hospitals
    • Plasma Centers
    Thought Leadership
    • White Papers & Clinical Reviews
    • Reference Lists
    • Poster Abstracts
    Education
    • Presentations
     
  • About Haemonetics
     
    Company Background
    • Overview
    • Historical Timeline
    • Leadership Team
    • Scientific Advisory Council
    • Office Locations
    Investor Relations
    • Investor Relations Home
    • Stock Information
    • Earnings
    • Forecasts & Guidance
    News & Events
    • In the News
    • Calendar of Events
    • Publications
    Careers
    • Careers Overview
    • Employee Spotlights
    • Open Positions

    Grants

    • Grant Program

     
  • Customer Support

Leaving U.S. website

You are now leaving the Haemonetics U.S. website, click 'Yes' to continue or 'No' to stay on the U.S. website.

YesNo
  • Home
  • Learning Center
  • Thought Leadership
  • Poster Abstracts
  • Contact Us
  • Print
  • Share

Poster Abstracts

  • AABB 2016

    Orlando, Florida

    • A novel approach for fat removal while maintaining blood quality in a discontinuous autotransfusion device - concept and evaluation
      Conclusions: Based on observations using a transparent centrifugation system, a hypothesis is presented to explain the accumulation of fat in the centrifuge bowl, both in spinning and stopped configurations. Modifications in process parameters and sequence resulted in the development of a dedicated fat removal program. This novel program significantly improves fat removal by the Latham bowl based autotransfusion device CS Elite, thus yielding results equivalent to the continuous autotransfusion system (CATS).
  • AABB 2012

    Boston, Massachusetts

    • Age of Blood Transfused In the United States: Data for 166,208 Transfusions
      Conclusions: For the hospitals studied, the current RBC supply chain and inventory management systems result in 47% of RBC units being transfused more than 3 weeks and 25% more than 4 weeks after their donation. Modifying the current supply chain to provide “fresher” blood will require substantial practice change and system redesign.
    • Blood Transfusion and Length of Stay: How Are They Related?
      Results: LOS was related to Nadir Hgb irrespective of transfusion status. Within each group of Nadir Hgb (except <7 g/dL), patients who received allogeneic blood had longer LOS than those who did not. Patients who received PAD (n=1179) had both longer LOS (3.50 vs. 3.07 days) and higher allogeneic transfusion rates (27.1% vs.17.3%) than those who did not receive PAD.
    • Variability in Transfusion Practice – Beyond Cardiac Surgery
      Methods: We queried a proprietary blood management business intelligence portal (IMPACT® Online, Haemonetics, Braintree, MA) and identified 9 noncardiac procedures associated with substantial red cell (RBC) transfusions. For each procedure, we determined the mean RBC transfusion and utilization rate for the entire hospital stay as well as the standard deviation (SD) of those rates among the participating hospitals (those that contributed at least 20 patients to each data set).
  • SABM 2012

    Pittsburgh, Pennsylvania

    • Periodic data review assures sustainability of blood management programs
      Results: Dramatic reductions in the use of PAD were achieved in each hospital. These improvements were not only sustained but continued during follow up. Similar success and sustainability was seen in the cardiac surgical interventions as reflected in decreased RBC utilization (units/patient including untransfused patients) for patients having coronary artery surgery (CABG).
    • Two unit dosing leads to excess transfusion
      Methods: Using a blood management business intelligence portal (IMPACT® Online, Haemonetics®, Braintree, MA) we determined the hematocrit at discharge of transfused patients who had either unilateral total hip or knee replacements during 2010 or 2011. From a group of 20,758 patients at 15 US hospitals, we removed 105 with incomplete data, 545 without a hematocrit following their last transfusion and 1,194 who received preoperatively donated autologous blood. Of the remaining 18,914, 3,033(16%) received allogeneic RBC.
  • Poster Archives

    Click here to view posters from previous years.
  • Contact Us
  • Terms of Use
  • Quality
  • Careers
  • Privacy Policy
  • Site Map

© 2011-2018 Haemonetics Corporation • 400 Wood Road • Braintree • MA • 02184 Website Feedback